AbbVie reports positive Crohn’s disease trial results for Skyrizi
AbbVie (ABBV) reported Phase 3 trial results for Skyrizi in Crohn's disease, showing 35.8% of patients achieved endoscopic remission vs. 9.1% with placebo. The study, presented at a medical conference, enrolled 289 patients. Skyrizi is under regulatory review for Crohn's disease treatment. The drug is already approved for other conditions.
How this was made
The 30-second read
Why it matters
The reported week-24 endoscopic remission and ulcer-free endoscopy rates, plus consistent safety and stronger response in treatment-naive advanced-therapy patients, can improve perceived probability of regulatory acceptance for the Crohn’s subcutaneous induction regimen.
Market read
Traders may adjust ABBV pipeline expectations and Crohn’s regulatory odds based on the specific week-24 efficacy readout and the absence of new safety signals.
What to watch
The article does not provide longer-term durability beyond week 24 or comparative data versus other Crohn’s standards, which may limit how far the market extrapolates.
Background
AbbVie’s Skyrizi (risankizumab-rzaa) is already approved for multiple indications, and this Phase 3 AFFIRM study evaluates subcutaneous induction for moderately to severely active Crohn’s disease.
Ticker impact
AbbVie reports positive Phase 3 AFFIRM results for subcutaneous Skyrizi in Crohn’s, with endoscopic remission 35.8% vs 9.1% at week 24.
Likely upward bias as traders price improved Crohn’s development/regulatory odds, though near-term reaction may be tempered by the FDA review timeline.
The article provides specific week-24 efficacy endpoints, safety consistency, and notes regulatory review for the subcutaneous induction regimen, which can drive sentiment and positioning.
Market effects
Reinforces IL-23 pathway competitiveness in inflammatory bowel disease, potentially affecting sentiment toward other IBD biologics.
Limited, as this is company-specific clinical data rather than a broad macro catalyst.
Moderate for global pharma/IBD investors due to FDA and EMA regulatory review mention.
Counterpoint
Despite positive results, the key commercial variable is regulatory approval timing and label scope for the subcutaneous induction regimen, which remains under review.
Key entities
- companyAbbVie
Sponsor of the Phase 3 AFFIRM study for Skyrizi in Crohn’s disease.
- drugSkyrizi (risankizumab-rzaa)
IL-23 p19 inhibitor evaluated for subcutaneous induction treatment in Crohn’s.
- regulatorsFDA and European Medicines Agency
Regulators currently reviewing the subcutaneous induction dosing regimen for Crohn’s.